[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Download PDF
Figure 1. Participant Assessment, Designation, and Outcomes
Figure 1. Participant Assessment, Designation, and Outcomes

ESRD indicates end-stage renal disease; RBC, red blood cell.
aEvaluation by a specialist and additional tests performed as needed.

Figure 2. Cumulative Incidence of Treated ESRD among Participants With and Without Persistent Asymptomatic Isolated Microscopic Hematuria
Figure 2. Cumulative Incidence of Treated ESRD among Participants With and Without Persistent Asymptomatic Isolated Microscopic Hematuria
Table 1. Baseline Characteristics of 1203626 Participants Examined between 1975-1997 According to Persistent Asymptomatic Isolated Microscopic Hematuria Category
Table 1. Baseline Characteristics of 1203626 Participants Examined between 1975-1997 According to Persistent Asymptomatic Isolated Microscopic Hematuria Category
Table 2. Characteristics of Participants With Treated End-Stage Renal Disease According to Persistent Asymptomatic Isolated Microscopic Hematuria Category
Table 2. Characteristics of Participants With Treated End-Stage Renal Disease According to Persistent Asymptomatic Isolated Microscopic Hematuria Category
Table 3. Association Between Persistent Asymptomatic Isolated Microscopic Hematuria and Treated End-Stage Renal Disease According to the Cox Proportional Hazards Models by Sex, Age at Study Enrollment, Decade of Enrollment, and Follow-up Perioda
Table 3. Association Between Persistent Asymptomatic Isolated Microscopic Hematuria and Treated End-Stage Renal Disease According to the Cox Proportional Hazards Models by Sex, Age at Study Enrollment, Decade of Enrollment, and Follow-up Perioda
1.
Cohen RA, Brown RS. Microscopic hematuria.  N Engl J Med. 2003;348(23):2330-2338PubMedArticle
2.
American Academy of Pediatrics and Committee on Practice and Ambulatory Medicine.  American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine: recommendations for preventive pediatric health care.  Pediatrics. 2000;105:645-646Article
3.
Committee on Practice and Ambulatory Medicine and Bright Futures Steering Committee.  Recommendations for preventive pediatric health care.  Pediatrics. 2007;120:1376Article
4.
Sutton JM. Evaluation of hematuria in adults.  JAMA. 1990;263(18):2475-2480PubMedArticle
5.
Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care.  BMJ. 2009;338:a3021PubMedArticle
6.
Dodge WF, West EF, Smith EH, Harvey Bruce III. Proteinuria and hematuria in schoolchildren: epidemiology and early natural history.  J Pediatr. 1976;88(2):327-347PubMedArticle
7.
Vehaskari VM, Rapola J, Koskimies O, Savilahti E, Vilska J, Hallman N. Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation.  J Pediatr. 1979;95(5, pt 1):676-684PubMedArticle
8.
Murakami M, Yamamoto H, Ueda Y, Murakami K, Yamauchi K. Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo.  Pediatr Nephrol. 1991;5(1):50-53PubMedArticle
9.
Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders, I: hematuria and proteinuria.  JAMA. 1989;262(9):1214-1219PubMedArticle
10.
Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults.  Clin Nephrol. 1996;45(5):281-288PubMed
11.
Hogg RJ. Screening for CKD in children: a global controversy.  Clin J Am Soc Nephrol. 2009;4(2):509-515PubMedArticle
12.
Israeli E, Schochat T, Korzets Z, Tekes-Manova D, Bernheim J, Golan E. Prehypertension and obesity in adolescents: a population study.  Am J Hypertens. 2006;19(7):708-712PubMedArticle
13.
Calderon-Margalit R, Gordon ES, Hoshen M, Kark JD, Rotem A, Haklai Z. Dialysis in Israel, 1989-2005—time trends and international comparisons.  Nephrol Dial Transplant. 2008;23(2):659-664PubMedArticle
14.
Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study.  Ann Stat. 1982;10:1100-1120Article
15.
Gordon C, Stapleton FB. Hematuria in adolescents.  Adolesc Med Clin. 2005;16(1):229-239PubMedArticle
16.
Shen P, He L, Jiang Y, Wang C, Chen M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria.  Int J Clin Pract. 2007;61(5):789-794PubMedArticle
17.
Eardley KS, Ferreira MAS, Howie AJ, Gosling P, Lipkin GW. Urinary albumin excretion: a predictor of glomerular findings in adults with microscopic haematuria.  QJM. 2004;97(5):297-301PubMedArticle
18.
Assadi FK. Value of urinary excretion of microalbumin in predicting glomerular lesions in children with isolated microscopic hematuria.  Pediatr Nephrol. 2005;20(8):1131-1135PubMedArticle
19.
Rao PK, Jones JS. How to evaluate “dipstick hematuria”: what to do before you refer.  Cleve Clin J Med. 2008;75(3):227-233PubMedArticle
20.
Tu WH, Shortliffe LD. Evaluation of asymptomatic, atraumatic hematuria in children and adults.  Nat Rev Urol. 2010;7(4):189-194PubMedArticle
21.
Donadio JV, Grande JP. IgA nephropathy.  N Engl J Med. 2002;347(10):738-748PubMedArticle
22.
Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen.  N Engl J Med. 2003;348(25):2543-2556PubMedArticle
23.
Tryggvason K, Patrakka J. Thin basement membrane nephropathy.  J Am Soc Nephrol. 2006;17(3):813-822PubMedArticle
24.
Kovacević Z, Jovanović D, Rabrenović V, Dimitrijević J, Djukanović J. Asymptomatic microscopic haematuria in young males.  Int J Clin Pract. 2008;62(3):406-412PubMedArticle
25.
Lee YM, Baek SY, Kim JH, Kim DS, Lee JS, Kim PK. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening.  Acta Paediatr. 2006;95(7):849-853PubMedArticle
26.
Park YH, Choi JY, Chung HS,  et al.  Hematuria and proteinuria in a mass school urine screening test.  Pediatr Nephrol. 2005;20(8):1126-1130PubMedArticle
27.
Chow KM, Kwan BC, Li PK, Szeto CC. Asymptomatic isolated microscopic haematuria: long-term follow-up.  QJM. 2004;97(11):739-745PubMedArticle
28.
Nieuwhof C, Doorenbos C, Grave W,  et al.  A prospective study of the natural history of idiopathic non-proteinuric hematuria.  Kidney Int. 1996;49(1):222-225PubMedArticle
29.
Topham PS, Harper SJ, Furness PN, Harris KP, Walls J, Feehally J. Glomerular disease as a cause of isolated microscopic haematuria.  Q J Med. 1994;87(6):329-335PubMed
30.
Voskarides K, Damianou L, Neocleous V,  et al.  COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy.  J Am Soc Nephrol. 2007;18(11):3004-3016PubMedArticle
31.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.  Arch Intern Med. 2004;164(6):659-663PubMedArticle
32.
Coresh J, Selvin E, Stevens LA,  et al.  Prevalence of chronic kidney disease in the United States.  JAMA. 2007;298(17):2038-2047PubMedArticle
33.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.  N Engl J Med. 2004;351(13):1296-1305PubMedArticle
Original Contribution
August 17, 2011

Persistent Asymptomatic Isolated Microscopic Hematuria in Israeli Adolescents and Young Adults and Risk for End-Stage Renal Disease

Author Affiliations

Author Affiliations: Israeli Defense Forces Medical Corps (Drs Vivante, Frenkel-Nir, Farfel, and Chaiter and Ms Tzur); Department of Pediatrics, Talpiot Medical Leadership Program, Edmond and Lily Safra Children's Hospital, Tel Hashomer (Dr Vivante); Sheba Medical Center, Tel Hashomer (Drs Vivante and Afek); Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv (Drs Vivante, Afek, Golan, and Shohat); Department of Nephrology; Rambam Health Care Campus, Rappaport Faculty of Medicine and Research Institute, The Technion–Israel Institute of Technology, Haifa (Dr Skorecki); Israel Renal Registry and Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba (Dr Golan); Israel Center for Disease Control, Ministry of Health, Jerusalem (Drs Shohat and Calderon-Margalit); and Hadassah-Hebrew University Braun School of Public Health, Jerusalem (Dr Calderon-Margalit), Israel.

JAMA. 2011;306(7):729-736. doi:10.1001/jama.2011.1141
Abstract

Context Few data are available on long-term outcomes among adolescents and young adults with persistent asymptomatic isolated microscopic hematuria.

Objective To evaluate the risk of end-stage renal disease (ESRD) in adolescents and young adults with persistent asymptomatic isolated microscopic hematuria.

Design, Setting, and Participants Nationwide, population-based, retrospective cohort study using medical data from 1 203 626 persons aged 16 through 25 years (60% male) examined for fitness for military service between 1975 and 1997 were linked to the Israeli treated ESRD registry. Incident cases of treated ESRD from January 1, 1980, to May 31, 2010, were included. Cox proportional hazards models were used to estimate the hazard ratio (HR) of treated ESRD among those diagnosed as having persistent asymptomatic isolated microscopic hematuria.

Main Outcome Measures Treated ESRD onset, defined as the date of initiation of dialysis treatment or the date of renal transplantation, whichever came first.

Results Persistent asymptomatic isolated microscopic hematuria was diagnosed in 3690 of 1 203 626 eligible individuals (0.3%). During 21.88 (SD, 6.74) years of follow-up, treated ESRD developed in 26 individuals (0.70%) with and 539 (0.045%) without persistent asymptomatic isolated microscopic hematuria, yielding incidence rates of 34.0 and 2.05 per 100 000 person-years, respectively, and a crude HR of 19.5 (95% confidence interval [CI], 13.1-28.9). A multivariate model adjusted for age, sex, paternal country of origin, year of enrollment, body mass index, and blood pressure at baseline did not substantially alter the risk associated with persistent asymptomatic isolated microscopic hematuria (HR, 18.5 [95% CI, 12.4-27.6]). A substantially increased risk for treated ESRD attributed to primary glomerular disease was found for individuals with persistent asymptomatic isolated microscopic hematuria compared with those without the condition (incidence rates, 19.6 vs 0.55 per 100 000 person-years, respectively; HR, 32.4 [95% CI, 18.9-55.7]). The fraction of treated ESRD attributed to microscopic hematuria was 4.3% (95% CI, 2.9%-6.4%).

Conclusion Presence of persistent asymptomatic isolated microscopic hematuria in persons aged 16 through 25 years was associated with significantly increased risk of treated ESRD for a period of 22 years, although the incidence and absolute risk remain quite low.

Persistent asymptomatic isolated microscopic hematuria is a frequent incidental finding on routine examination of children, adolescents, and young adults.1 The most recent American Academy of Pediatrics guidelines rescinded the recommendation for urine screening during the second decade of life.2,3 Microscopic hematuria is commonly screened by the urinary dipstick test, and positive results usually prompt microscopic examination, the gold standard for detecting microscopic hematuria.1,4 The definitions of microscopic hematuria vary from 2 to more than 10 erythrocytes per high-power field.1,4 Microscopic hematuria can be either an isolated finding accompanied by other kidney abnormalities or part of a systemic condition. It also can be transient or persistent.

The extent to which adolescents and young adults with persistent asymptomatic isolated microscopic hematuria should be evaluated is unclear.5 Moreover, the source frequently remains undetected, and most patients are diagnosed as having persistent asymptomatic isolated microscopic hematuria of unknown origin.1 Only a few population-based studies have addressed the long-term outcomes of the condition among adolescents and young adults, and data are lacking on long-term outcomes of large cohorts,610 leading to considerable controversy over appropriate evaluation, management, and prognosis.11 We conducted a nationwide, population-based, retrospective cohort study to evaluate the risk of treated end-stage renal disease (ESRD) in adolescents and young adults with persistent asymptomatic isolated microscopic hematuria.

METHODS
Study Participants

One year prior to their conscription into military service, all eligible Israeli adolescents undergo obligatory medical board examination for health status assessment that includes reviewing the medical file obtained from the primary care physician, taking a medical history and conducting a physical examination (including routine urinalysis), and, if needed, providing referral for further evaluation. All potential recruits undergo baseline measurement of weight and height and a sphygmomanometric blood pressure measurement obtained at the right arm in the seated position.12

Inclusion criteria for the current study were age 16 through 25 years at the time of medical board examination between 1975 and 1997. Because military service is not mandatory for Israeli non-Jews, the study population included only Jewish recruits, for whom military service is compulsory. Exclusion criteria were the presence of any of the following diagnoses: diabetes mellitus, systemic lupus erythematosus, vasculitis, hypertension, or any known past or current kidney disease at the time of enrollment, including congenital or acquired anomalies of the kidneys or urinary tract, glomerulonephritis, nephrolithiasis, cystic renal disease, urinary tract infection, acute or chronic kidney injury, and proteinuria. Proteinuria was defined by urine dipstick testing. Dipstick levels of 1+ or higher recorded during the initial urinalysis screen were designated as positive and triggered 2 subsequent confirmatory dipstick tests. Participants with at least 1 positive confirmatory result were referred for 24-hour assessment of urine quantitative protein excretion and to a board-certified nephrologist for determination of a specific proteinuria-related diagnosis. Participants with quantitative protein excretion exceeding 200 mg/24 h were excluded from the study cohort.

Diagnosis of Persistent Asymptomatic Isolated Microscopic Hematuria

Participants enrolled in the study were initially screened for the presence of microscopic hematuria by the urinary dipstick test, followed by sediment examination by urine microscopy if the dipstick result was positive. The diagnostic criteria for persistent asymptomatic isolated microscopic hematuria were: (1) 5 or more red blood cells per high-power field for urine specimens obtained on 3 separate occasions on different days (female participants were instructed to avoid testing during menstruation); (2) serum creatinine values within the normal range; (3) no abnormalities detected on renal imaging studies (which consisted of intravenous pyelographic contrast imaging performed from 1975 to the late 1980s and renal urinary tract and bladder ultrasound from the late 1980s to the end of enrollment in 1997); (4) being otherwise asymptomatic, with hematuria as the sole finding and not attributed to other known or apparent disease; and (5) further evaluation and confirmation of the diagnosis of asymptomatic isolated microscopic hematuria by a board-certified nephrologist. Participants who fulfilled these criteria for persistent asymptomatic isolated microscopic hematuria were then assigned a specific code number.

The Israeli Treated ESRD Registry

The Israeli treated ESRD database is a national administrative registry maintained by the Ministry of Health.13 It contains information on patients receiving any form of renal replacement therapy, ie, hemodialysis, peritoneal dialysis, or kidney transplantation. All nephrology dialysis units in Israel report to the Ministry of Health on new patients receiving renal replacement therapy and changes in treatment modality. The database includes demographic data, a primary diagnosis, and initial modality of renal replacement therapy, as well as dates of initiating dialysis, change of dialysis treatment modalities, renal transplantation, and death. Validation of the treated ESRD database includes periodic linkage with the Israeli population registry to update demographic and mortality data. Reports of cadaver-donor transplants in Israel are crosschecked with the National Laboratory for Tissue Matching, and reports on living donor kidney transplants are crosschecked with the National Transplant Center. A single primary diagnosis is recorded for each new patient in the treated ESRD database.13 The current study cohort was linked to the Israeli treated ESRD registry using the identification number given to all Israeli citizens at the time of birth or immigration.

The institutional review boards of both the Israel Defense Forces and Sheba Medical Center approved the study and waived the requirement for informed consent on the basis of preserving participants' anonymity.

Outcome Variables and Follow-up

Onset of treated ESRD was defined as the date of initiation of dialysis treatment or the date of renal transplantation, whichever came first, and all treated ESRD cases from January 1, 1980, to May 31, 2010, were included. The causes of treated ESRD were categorized as diabetes, hypertension, glomerulonephritis (including a subcategory for IgA nephropathy), hereditary nephritis, interstitial nephritis, cystic kidney disease, secondary glomerulonephritis, drug-induced, and other causes. The etiology was recorded by the responsible nephrologist at the medical center where the patient was receiving renal replacement therapy; 23% of patients had missing information on etiology of treated ESRD. Follow-up period was measured from the initial medical board assessment until the initiation of renal replacement therapy (incidence of ESRD), death, or May 31, 2010, whichever came first.

Statistical Analysis

Summary statistics for the study group were expressed as mean (SD) or percentage. Cox proportional hazards models14 were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for comparing the incidence of treated ESRD among participants with and without persistent asymptomatic isolated microscopic hematuria. The proportional hazards assumption was tested graphically using log–minus-log graphs. Models were constructed controlling for age, sex, paternal country of origin (Europe/Americas, West Asia, North Africa, and Israel) and period of baseline examination by decade. Additional models controlled for body mass index (BMI) below or above the cutoff for overweight (the sex-specific 85th percentile, ie, 24.2 for male and 24.5 for female participants, calculated as weight in kilograms divided by height in meters squared) and for mean arterial blood pressure, calculated as 2/3 diastolic blood pressure + 1/3 systolic blood pressure and categorized as below or above the sex-specific 90th percentile (98.3 mm Hg for male and 96.7 mm Hg for female participants).

Data were complete for all variables except for BMI, mean arterial pressure, and paternal country of origin, which were available for 96.7%, 91.9%, and 88% of the study population, respectively, with missing values receiving a separate category in the models.

Stratified analyses were conducted by strata of sex, age at enrollment, decade of enrollment, and years of follow-up. Sensitivity analyses were restricted to participants who had at least 5 years of follow-up, treated ESRD diagnosed from 1989, and best-worst scenario analysis for ESRD due to primary glomerular disease. This latter analysis considered the following diagnoses as ESRD due to primary glomerular disease: hereditary nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, membranous nephropathy, glomerulonephritis not otherwise specified, and rapidly progressive glomerulonephritis. In best-worst scenario analyses, all or none, respectively, of the missing etiologies were designated as primary glomerular disease. The models used for all 3 scenarios were the same as those used for the whole cohort.

P < .05 (2-sided) was considered to indicate statistical significance. All statistical analyses were conducted using SPSS version 18 (SPSS Inc, Chicago, Illinois).

RESULTS
Study Population

The cohort comprised 1 203 626 male and female adolescents and young adults (60% male). Of the 1 203 626 participants who met entry criteria, 3690 (0.3%; annual range, 0.1%-0.5%) were diagnosed as having persistent asymptomatic isolated microscopic hematuria, and 1 199 936 were negative for this condition (Figure 1). The condition at enrollment was twice as prevalent among male as female participants (0.4% and 0.2%, respectively). Among participants with and without persistent asymptomatic isolated microscopic hematuria, the mean age at recruitment was 17.6 (SD, 1.2) and 17.3 (SD, 1.1) years, respectively, and the duration of follow-up was 20.7 (SD, 5.9) and 21.9 (SD, 6.7) years, respectively. BMI and blood pressure values at study enrollment according to sex subcategories for both groups were similar (Table 1).

Persistent Asymptomatic Isolated Microscopic Hematuria and Treated ESRD

During 26 278 598 person-years of follow-up, 565 participants developed treated ESRD, for an overall incidence rate of 2.15 per 100 000 person-years. The characteristics of those who developed treated ESRD, by study group, are reported in Table 2. Baseline data for participants with persistent asymptomatic isolated microscopic hematuria who developed ESRD (n = 26 [0.7%]) were similar to those of participants without the condition who developed ESRD (n = 539 [0.04%]) in all aspects except for BMI: the former had lower BMI levels compared with the latter (mean, 20.6 [SD, 2.87] and 22.9 (SD, 4.33], respectively; P = .001). Participants with persistent asymptomatic isolated microscopic hematuria were younger at ESRD diagnosis compared with their counterparts (mean age at diagnosis, 34.7 [SD, 6.6] and 38.6 [SD, 8.5] years, respectively; P = .02) andhad a shorter follow-up (Table 2). The mean age at the end of follow-up was 38.4 (SD, 8.4) years (range, 18-60 years).

Figure 2 shows the association between persistent asymptomatic isolated microscopic hematuria and treated ESRD during the follow-up period. The incidence rates of treated ESRD were 34.0 (95% CI, 22.2-49.9) per 100 000 person-years among participants with persistent asymptomatic isolated microscopic hematuria and 2.05 (95% CI, 1.88-2.23) per 100 000 person-years among those without the condition, yielding an unadjusted HR of 19.5 (95% CI, 13.1-28.9). Controlling for age, sex, paternal country of origin, period of enrollment, BMI, and blood pressure at baseline had minimal effect on these estimated HRs for treated ESRD (HR, 18.5 [95% CI, 12.4-27.6]) (Table 3). Restricting the study population to those who had at least 5 years of follow-up also did not materially change the HR estimate (19.2 [95% CI, 12.9-28.6]).

To exclude the possibility of misclassification bias attributable to less accurate imaging techniques during the initial years of the study and to eliminate concern that dates of treated ESRD incidence before 1989 were inaccurate, we analyzed treated ESRD in a subgroup of participants enrolled after 1989, all of whom underwent renal ultrasonography. Persistent asymptomatic isolated microscopic hematuria among the 587 211 participants diagnosed after 1989 was still strongly and independently associated with treatedESRD (HR, 18.9 [95% CI, 6.81-52.2]). We further studied the association for the whole population with logistic regression and with imputation of different incidence dates between 1980-1988, and those analyses yielded identical estimates. The fraction of treated ESRD attributed to microhematuria was 4.3% (95% CI, 2.9%-6.4%).

Risk Factors for Specific Causes of Treated ESRD

Reported etiologies for ESRD by study group are reported in Table 2. We further analyzed persistent asymptomatic isolated microscopic hematuria as a risk factor for specific treated ESRD etiologies. Incidence rates of primary glomerular disease–associated ESRD were 19.6 (95% CI, 11.0-32.4) vs 0.55 (95% CI, 0.47-0.65) per 100 000 person-years among participants with and without the condition, respectively. The HR for treated ESRD attributed to primary glomerular disease, adjusted for age, sex, country of paternal origin, study period, BMI, and mean arterial pressure, was 32.4 (95% CI, 18.9-55.7). In a best-worst sensitivity analysis, assuming all missing etiologies of ESRD in the control group were attributable to primary glomerular disease yielded an HRof 18.8 (95% CI, 11.1-31.8). The assumption that all missing etiologies in the group with hematuria were attributable to primary glomerular disease yielded an HR of 43.1 (95% CI, 26.7-69.4).

COMMENT

In this long-term, nationwide, population-based, retrospective cohort study, persistent asymptomatic microscopic hematuria was strongly associated with the incidence of treated ESRD. These results were independent of potential ESRD risk confounders, such as age, sex, country of origin, BMI, and blood pressure. Our results suggest that persistent asymptomatic isolated microscopic hematuria among adolescents and young adults may be a strong predictive risk marker of future ESRD, attributable mostly to glomerular disease as the primary etiology.

Several limitations of this study warrant consideration. First, the annual prevalence of asymptomatic isolated microscopic hematuria was relatively low in the period 1975-1979 (0.1%-0.2%) compared with subsequent years (0.2%-0.5%).15 Second, data on persistent asymptomatic isolated microscopic hematuria were collected from 1975 forward, whereas data on treated ESRD were collected from 1980 forward. We addressed these issues by stratifying our analyses by year of cohort enrollment and follow-up period, which yielded similar results.

Third, clinical information, such as normal baseline creatinine levels and normal findings from renal imaging studies for the participants with hematuria, were reported rather than measured. Therefore, we do not have participants' glomerular filtration rate values. Fourth, we cannot rule out the possibility that trace dipstick proteinuria may have remained undetected or unreported during the initial screening; it is possible that some participants who subsequently developed treated ESRD had microalbuminuria, a suggested risk factor for ESRD among patients with microscopic hematuria.1618 Nevertheless, even if this were the case, microscopic hematuria would still represent an important clinical marker for an increased risk of renal disease in these participants, in the absence of abnormal measures for these other clinical indices of renal injury at the time of screening assessment. Last, our study was limited to Jewish recruits, so its generalizability may be limited.

The strengths of our study are that it included very large cohorts with detailed clinical assessment parameters together with a long follow-up period and comprehensive documentation of ESRD, thereby enabling the determination of the risks for this disease with relatively low incidence. Moreover, persistent asymptomatic isolated microscopic hematuria was diagnosed only after a nephrologic assessment had excluded other renal pathologies.

The availability of such a large mass-screening setup enabled us to establish that the prevalence of persistent asymptomatic isolated microscopic hematuria was 0.3% among adolescents and young adults. This value is within the lower range of previously reported prevalence,1,7,9,15 most likely because we required persistence of hematuria and microscopic confirmation rather than relying solely on isolated dipstick tests, which reportedly yield high rates of false-positive results.19 In addition, the workup of positive hematuria cases (ie, renal function tests and kidney imaging studies in addition to a nephrologist's evaluation) excluded other known causes of persistent microscopic hematuria, such as congenital renal malformations and urolithiasis.20

We found male predominance among participants with persistent asymptomatic isolated microscopic hematuria. This is in line with the male predominance reported in IgA nephropathy21 and hereditary nephritis22 and unlike the reported finding of possible mild female predominance in thin basement membrane disease.23 Those 3 etiologies are considered by most authors to be predominant for persistent asymptomatic isolated microscopic hematuria in this age group.2429 The association with progression to chronic kidney disease is best established for IgA nephropathy21 and Alport syndrome.22 In contrast, thin basement membrane disease, a common etiology for microscopic hematuria, had been considered benign by most authors, although recent studies have suggested otherwise.23,30 Because renal biopsies are not typically part of the evaluation of microscopic hematuria, it is difficult to estimate the prevalence of cases clearly attributable to each disease category and to efficiently predict the risk for future chronic kidney disease among patients with persistent asymptomatic isolated microscopic hematuria. Among the treated ESRD etiologies of those patients in the current study, we found IgA nephropathy and hereditary nephritis to contribute equally to its occurrence. Moreover, hereditary nephritis may be much more widespread than commonly believed, and some cases may have been misdiagnosed as benign thin basement membrane disease.23,30

Among participants with hematuria, early detection of ESRD with more assiduous follow-up might bias the results. Nevertheless, early detection of chronic kidney disease likely would have triggered therapeutic interventions with the potential of slowing progression to ESRD, decreasing rather than increasing the hazard ratio. Treated ESRD is an advanced clinical outcome, and its detection and universal registration in the Israeli health care system should not be influenced by diligence of health care follow-up, in contrast to early presymptomatic stages of chronic kidney disease. Another potential bias is that intravenous pyelographic contrast imaging performed for evaluation prior to 1989 could have caused increased kidney failure; however, restricting our study population to the post-1989 subgroup did not materially change the results.

In our study, participants with ESRD and with persistent asymptomatic isolated microscopic hematuria were considerably younger at ESRD onset compared with those with ESRD and no similar history (mean age at diagnosis, 34 vs 38 years, respectively). This may be related to the difference in underlying renal diseases between the study groups (Table 2). The condition was associated with an increased relative risk for the development of ESRD attributable to primary glomerular disease (multivariate-adjusted HR, 32.4 [95% CI, 18.9-55.7]). Consequently, our findings suggest that persistent asymptomatic isolated microscopic hematuria detected during adolescence and young adulthood is an early marker for primary glomerular injury and may be the first sign of an occult renal disease. As such, there may be a window during which the diagnosis of asymptomatic isolated microscopic hematuria following urine screening can provide an alert to the future development of symptoms or renal failure.

Follow-up ended before the study population reached the age at which ESRD peaks. ESRD is rare in young adults, as reflected by the low incidence rates observed in our study. However, because ESRD is the tip of the iceberg, estimated to represent only 2% of all patients with chronic kidney disease, interpretation of our findings should consider the much wider spectrum and far larger numbers of individuals with chronic kidney disease.31,32 Therefore, demonstrating that persistent isolated microscopic hematuria is a risk marker for ESRD highlights the importance of early detection of predialysis chronic kidney disease for the application of current and future strategies to slow the deterioration to ESRD. It also shows the importance of considering complications and comorbid conditions across the range of chronic kidney disease.33

Our study was not designed to examine the effectiveness of mass screening for microscopic hematuria in children and young adults. However, the additional cases attributed to persistent microhematuria, even if few, because they represent individuals who are younger at ESRD onset, probably represent loss of many quality-adjusted life years owing to productivity loss and to ESRD-related comorbid conditions. In light of our findings, future studies are warranted to evaluate the utility of population screening in improving clinical outcomes.

Back to top
Article Information

Corresponding Author: Asaf Vivante, MD, Israeli Defense Forces Medical Corps and Talpiot Medical Leadership Program, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer 52621, Israel (asafvivante@gmail.com).

Author Contributions: Drs Vivante and Calderon-Margalit had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vivante, Afek, Frenkel-Nir, Tzur, Farfel, Golan, Shohat, Skorecki, Calderon-Margalit.

Acquisition of data: Vivante, Afek, Frenkel-Nir, Tzur, Golan, Chaiter, Shohat.

Analysis and interpretation of data: Vivante, Afek, Frenkel-Nir, Tzur, Farfel, Chaiter, Shohat, Skorecki, Calderon-Margalit.

Drafting of the manuscript: Vivante, Afek, Frenkel-Nir, Tzur, Farfel, Chaiter, Shohat, Skorecki, Calderon-Margalit.

Critical revision of the manuscript for important intellectual content: Vivante, Afek, Farfel, Golan, Chaiter, Shohat, Skorecki, Calderon-Margalit.

Statistical analysis: Calderon-Margalit.

Administrative, technical, or material support: Vivante, Frenkel-Nir, Tzur.

Study supervision: Vivante, Golan, Skorecki.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: Access to anonymized databases was provided by the Israel Defense Forces (IDF) Medical Corps and the Israeli Ministry of Health.

Role of Sponsor: Neither the IDF Medical Corps nor the Israeli Ministry of Health were involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

Additional Contributions: We thank Amir Tirosh, MD, PhD (Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School), for his valuable comments. Dr Tirosh received no compensation for his contributions.

REFERENCES
1.
Cohen RA, Brown RS. Microscopic hematuria.  N Engl J Med. 2003;348(23):2330-2338PubMedArticle
2.
American Academy of Pediatrics and Committee on Practice and Ambulatory Medicine.  American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine: recommendations for preventive pediatric health care.  Pediatrics. 2000;105:645-646Article
3.
Committee on Practice and Ambulatory Medicine and Bright Futures Steering Committee.  Recommendations for preventive pediatric health care.  Pediatrics. 2007;120:1376Article
4.
Sutton JM. Evaluation of hematuria in adults.  JAMA. 1990;263(18):2475-2480PubMedArticle
5.
Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care.  BMJ. 2009;338:a3021PubMedArticle
6.
Dodge WF, West EF, Smith EH, Harvey Bruce III. Proteinuria and hematuria in schoolchildren: epidemiology and early natural history.  J Pediatr. 1976;88(2):327-347PubMedArticle
7.
Vehaskari VM, Rapola J, Koskimies O, Savilahti E, Vilska J, Hallman N. Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation.  J Pediatr. 1979;95(5, pt 1):676-684PubMedArticle
8.
Murakami M, Yamamoto H, Ueda Y, Murakami K, Yamauchi K. Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo.  Pediatr Nephrol. 1991;5(1):50-53PubMedArticle
9.
Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders, I: hematuria and proteinuria.  JAMA. 1989;262(9):1214-1219PubMedArticle
10.
Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults.  Clin Nephrol. 1996;45(5):281-288PubMed
11.
Hogg RJ. Screening for CKD in children: a global controversy.  Clin J Am Soc Nephrol. 2009;4(2):509-515PubMedArticle
12.
Israeli E, Schochat T, Korzets Z, Tekes-Manova D, Bernheim J, Golan E. Prehypertension and obesity in adolescents: a population study.  Am J Hypertens. 2006;19(7):708-712PubMedArticle
13.
Calderon-Margalit R, Gordon ES, Hoshen M, Kark JD, Rotem A, Haklai Z. Dialysis in Israel, 1989-2005—time trends and international comparisons.  Nephrol Dial Transplant. 2008;23(2):659-664PubMedArticle
14.
Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study.  Ann Stat. 1982;10:1100-1120Article
15.
Gordon C, Stapleton FB. Hematuria in adolescents.  Adolesc Med Clin. 2005;16(1):229-239PubMedArticle
16.
Shen P, He L, Jiang Y, Wang C, Chen M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria.  Int J Clin Pract. 2007;61(5):789-794PubMedArticle
17.
Eardley KS, Ferreira MAS, Howie AJ, Gosling P, Lipkin GW. Urinary albumin excretion: a predictor of glomerular findings in adults with microscopic haematuria.  QJM. 2004;97(5):297-301PubMedArticle
18.
Assadi FK. Value of urinary excretion of microalbumin in predicting glomerular lesions in children with isolated microscopic hematuria.  Pediatr Nephrol. 2005;20(8):1131-1135PubMedArticle
19.
Rao PK, Jones JS. How to evaluate “dipstick hematuria”: what to do before you refer.  Cleve Clin J Med. 2008;75(3):227-233PubMedArticle
20.
Tu WH, Shortliffe LD. Evaluation of asymptomatic, atraumatic hematuria in children and adults.  Nat Rev Urol. 2010;7(4):189-194PubMedArticle
21.
Donadio JV, Grande JP. IgA nephropathy.  N Engl J Med. 2002;347(10):738-748PubMedArticle
22.
Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen.  N Engl J Med. 2003;348(25):2543-2556PubMedArticle
23.
Tryggvason K, Patrakka J. Thin basement membrane nephropathy.  J Am Soc Nephrol. 2006;17(3):813-822PubMedArticle
24.
Kovacević Z, Jovanović D, Rabrenović V, Dimitrijević J, Djukanović J. Asymptomatic microscopic haematuria in young males.  Int J Clin Pract. 2008;62(3):406-412PubMedArticle
25.
Lee YM, Baek SY, Kim JH, Kim DS, Lee JS, Kim PK. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening.  Acta Paediatr. 2006;95(7):849-853PubMedArticle
26.
Park YH, Choi JY, Chung HS,  et al.  Hematuria and proteinuria in a mass school urine screening test.  Pediatr Nephrol. 2005;20(8):1126-1130PubMedArticle
27.
Chow KM, Kwan BC, Li PK, Szeto CC. Asymptomatic isolated microscopic haematuria: long-term follow-up.  QJM. 2004;97(11):739-745PubMedArticle
28.
Nieuwhof C, Doorenbos C, Grave W,  et al.  A prospective study of the natural history of idiopathic non-proteinuric hematuria.  Kidney Int. 1996;49(1):222-225PubMedArticle
29.
Topham PS, Harper SJ, Furness PN, Harris KP, Walls J, Feehally J. Glomerular disease as a cause of isolated microscopic haematuria.  Q J Med. 1994;87(6):329-335PubMed
30.
Voskarides K, Damianou L, Neocleous V,  et al.  COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy.  J Am Soc Nephrol. 2007;18(11):3004-3016PubMedArticle
31.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.  Arch Intern Med. 2004;164(6):659-663PubMedArticle
32.
Coresh J, Selvin E, Stevens LA,  et al.  Prevalence of chronic kidney disease in the United States.  JAMA. 2007;298(17):2038-2047PubMedArticle
33.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.  N Engl J Med. 2004;351(13):1296-1305PubMedArticle
×